GLP-1 agonists in Type 1 diabetes – Indications and use

Q2 Medicine

Obesity Medicine Pub Date : 2025-02-11 DOI:10.1016/j.obmed.2025.100591

Panadeekarn Panjawatanan, Richard J. Comi

{"title":"GLP-1 agonists in Type 1 diabetes – Indications and use","authors":"Panadeekarn Panjawatanan, Richard J. Comi","doi":"10.1016/j.obmed.2025.100591","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Insulin therapy in Type 1 diabetes is associated with weight gain. Glucagon-like peptide 1 (GLP-1) agonists, which lower blood glucose and promote weight loss, may help reverse this trend and reduce hemoglobin A1C (A1C) levels.</div></div><div><h3>Methods</h3><div>Patients with Type 1 diabetes with concomitant GLP-1 agonists used for at least one year were included. Observed outcomes were the change in A1C, weight, and basal insulin use compared at baseline and 12 months using mixed models repeated measures.</div></div><div><h3>Results</h3><div>Forty-nine patients with weight gain were included. Prior to treatment, patients gained an average of 2.0 kg annually over three years. After 12 months of GLP-1 agonist therapy, weight significantly decreased from 97.6 kg (95% CI: 92.7–102.5) to 90.0 kg (95% CI: 84.9–95.1) (p < 0.001). A1C levels also improved significantly, from 8.2% (95% CI: 7.9–8.6) to 7.6% (95% CI: 7.2–7.9) (p < 0.001). Basal insulin requirements were significantly reduced.</div></div><div><h3>Conclusion</h3><div>We conclude that GLP-1 agonists effectively reverse the trend of weight gain and improve A1C levels in patients with Type 1 diabetes.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100591"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451847625000119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Insulin therapy in Type 1 diabetes is associated with weight gain. Glucagon-like peptide 1 (GLP-1) agonists, which lower blood glucose and promote weight loss, may help reverse this trend and reduce hemoglobin A1C (A1C) levels.

Methods

Patients with Type 1 diabetes with concomitant GLP-1 agonists used for at least one year were included. Observed outcomes were the change in A1C, weight, and basal insulin use compared at baseline and 12 months using mixed models repeated measures.

Results

Forty-nine patients with weight gain were included. Prior to treatment, patients gained an average of 2.0 kg annually over three years. After 12 months of GLP-1 agonist therapy, weight significantly decreased from 97.6 kg (95% CI: 92.7–102.5) to 90.0 kg (95% CI: 84.9–95.1) (p < 0.001). A1C levels also improved significantly, from 8.2% (95% CI: 7.9–8.6) to 7.6% (95% CI: 7.2–7.9) (p < 0.001). Basal insulin requirements were significantly reduced.

Conclusion

We conclude that GLP-1 agonists effectively reverse the trend of weight gain and improve A1C levels in patients with Type 1 diabetes.

查看原文本刊更多论文

GLP-1激动剂在1型糖尿病中的应用

目的：1型糖尿病胰岛素治疗与体重增加相关。胰高血糖素样肽1 （GLP-1）激动剂可以降低血糖，促进体重减轻，可能有助于扭转这一趋势，降低血红蛋白A1C （A1C）水平。方法纳入合并GLP-1激动剂治疗至少一年的1型糖尿病患者。观察结果是使用混合模型重复测量比较基线和12个月时A1C、体重和基础胰岛素使用的变化。结果纳入49例体重增加患者。在治疗前，患者在三年内平均每年增加2.0公斤。经过12个月的GLP-1激动剂治疗，体重从97.6 kg （95% CI: 92.7-102.5）显著下降到90.0 kg (95% CI: 84.9-95.1) (p <；0.001)。A1C水平也显著改善，从8.2% （95% CI: 7.9-8.6）降至7.6% (95% CI: 7.2-7.9) (p <；0.001)。基础胰岛素需要量显著降低。结论GLP-1激动剂可有效逆转1型糖尿病患者体重增加趋势，改善A1C水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Medicine Medicine-Public Health, Environmental and Occupational Health

CiteScore

5.50

自引率

0.00%

发文量

审稿时长

40 days

期刊介绍： The official journal of the Shanghai Diabetes Institute Obesity is a disease of increasing global prevalence with serious effects on both the individual and society. Obesity Medicine focusses on health and disease, relating to the very broad spectrum of research in and impacting on humans. It is an interdisciplinary journal that addresses mechanisms of disease, epidemiology and co-morbidities. Obesity Medicine encompasses medical, societal, socioeconomic as well as preventive aspects of obesity and is aimed at researchers, practitioners and educators alike.